Obermatt

Flags

Financial distress

Handok

KSC:002390 · KR7002390003
PharmaceuticalsSmall

360

15
Medium confidence — indicative
Profit price16
Owner Earnings Yield57
Dividend Yield1
Price/Sales95
EV / Gross Profit39
Price/Book89
Return on Capital59
Cash Return on Capital60
Return on Equity53
EBIT Margin47
Gross Profitability40
Accruals48
Owner Earnings Margin56
Sales growth78
Profit growth89
Reinvestment21
Price momentum18
Debt load5
Refinancing98
Debt Payback6
Liquidity26
Analyst ratings
Expectations trend
Market mood55
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Handok clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Employees157
ISINKR7002390003
Last UpdateApr 2, 2026
Themes
DiabetesHealth DiagnosticsNutraceuticalPharmaceutical

Description

Analysis

Middle-of-the-road

HANDOK Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is attractive. The owner-earnings multiple stands at 12.2×; owner earnings: the cash an owner could take out each year.

Growth is mixed; the safety picture is fragile. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
36
2026

All-time high

36

Jun 2026

All-time low

1

Mar 2026

Average rank

19

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
95
Price/Earnings
Price/Book
89
Dividend Yield
1
Value (overall)
67

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Handok with its peers
Yuhan
KSC:000100
32
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Chunghwa Chemical Synthesis & Biotech
TAI:1762
13
CountryTaiwan
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Green Cross
KSC:005250
28
CountrySouth Korea
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Dong-A ST
KSC:170900
39
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
PharmGen Science
KSC:004720
74
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →